CURRENT Medical Diagnosis and
Treatment 2026
65th Edition
Author(s)Maxine A. Papadakis; Michael
W. Rabow; Kenneth R. McQuaid; Paul L.
Nadler; Erika Leemann Price
TEST BANK
Part A — Disease Prevention & Health Promotion (Ch. 1) — 5
items
1) Reference
Ch. 1 — Disease Prevention & Health Promotion
,Question Stem
A healthy 48-year-old man with no family history of colorectal
cancer asks when he should start routine colorectal cancer
screening. According to current CMDT screening
recommendations, which is the best next step?
A. Begin screening now with colonoscopy every 10 years.
B. Defer screening until age 50 given his low risk.
C. Begin screening now with stool-based test (annual FIT) or
colonoscopy at age 50.
D. Begin screening now; average-risk screening should start at
age 45.
Correct Answer
D
Rationales
Correct: CMDT endorses average-risk colorectal cancer
screening beginning at age 45 (shared by major societies and
reflected in CMDT), so initiating screening now (age 48) is
appropriate.
A: Colonoscopy every 10 years is a valid modality, but the
option’s wording implying “begin now with colonoscopy” is
reasonable — however D is a clearer statement of the age
threshold.
B: Deferring to 50 is outdated; CMDT supports starting at 45 for
average-risk adults.
C: Recommending stool-based tests is acceptable, but stating
,“or colonoscopy at age 50” conflicts with the age-45 start; thus
less appropriate.
Teaching Point
Average-risk colorectal cancer screening begins at age 45.
Papadakis et al. (2025). CURRENT Medical Diagnosis &
Treatment 2026 (65th Ed.). Ch. 1.
accessmedicine.mhmedical.com
2) Reference
Ch. 1 — Disease Prevention & Health Promotion
Question Stem
A 66-year-old woman with type 2 diabetes asks whether she
should take low-dose aspirin to prevent a first myocardial
infarction. Which response best reflects CMDT guidance for
primary prevention in older adults?
A. Recommend daily low-dose aspirin because age >65
automatically benefits.
B. Recommend aspirin only if her 10-year ASCVD risk is high and
bleeding risk low.
C. Advise against aspirin because it is contraindicated in all
adults >60.
D. Recommend aspirin for diabetes alone regardless of
cardiovascular risk.
, Correct Answer
B
Rationales
Correct: CMDT emphasizes individualized primary prevention
decisions — aspirin may be considered when 10-year ASCVD
risk is sufficiently high and bleeding risk is low; routine use in
older adults without individualized risk assessment is not
recommended.
A: Age alone is not an automatic indication; bleeding risk
matters.
C: Aspirin is not absolutely contraindicated in all adults >60;
blanket prohibition is incorrect.
D: Diabetes increases risk but does not automatically mandate
aspirin without weighing bleeding risk and overall ASCVD risk.
Teaching Point
Primary aspirin use requires individualized ASCVD vs bleeding-
risk assessment.
Papadakis et al. (2025). CURRENT Medical Diagnosis &
Treatment 2026 (65th Ed.). Ch. 1.
accessmedicine.mhmedical.com
3) Reference
Ch. 1 — Disease Prevention & Health Promotion
Question Stem
A 30-year-old woman is uncertain whether to receive HPV
Treatment 2026
65th Edition
Author(s)Maxine A. Papadakis; Michael
W. Rabow; Kenneth R. McQuaid; Paul L.
Nadler; Erika Leemann Price
TEST BANK
Part A — Disease Prevention & Health Promotion (Ch. 1) — 5
items
1) Reference
Ch. 1 — Disease Prevention & Health Promotion
,Question Stem
A healthy 48-year-old man with no family history of colorectal
cancer asks when he should start routine colorectal cancer
screening. According to current CMDT screening
recommendations, which is the best next step?
A. Begin screening now with colonoscopy every 10 years.
B. Defer screening until age 50 given his low risk.
C. Begin screening now with stool-based test (annual FIT) or
colonoscopy at age 50.
D. Begin screening now; average-risk screening should start at
age 45.
Correct Answer
D
Rationales
Correct: CMDT endorses average-risk colorectal cancer
screening beginning at age 45 (shared by major societies and
reflected in CMDT), so initiating screening now (age 48) is
appropriate.
A: Colonoscopy every 10 years is a valid modality, but the
option’s wording implying “begin now with colonoscopy” is
reasonable — however D is a clearer statement of the age
threshold.
B: Deferring to 50 is outdated; CMDT supports starting at 45 for
average-risk adults.
C: Recommending stool-based tests is acceptable, but stating
,“or colonoscopy at age 50” conflicts with the age-45 start; thus
less appropriate.
Teaching Point
Average-risk colorectal cancer screening begins at age 45.
Papadakis et al. (2025). CURRENT Medical Diagnosis &
Treatment 2026 (65th Ed.). Ch. 1.
accessmedicine.mhmedical.com
2) Reference
Ch. 1 — Disease Prevention & Health Promotion
Question Stem
A 66-year-old woman with type 2 diabetes asks whether she
should take low-dose aspirin to prevent a first myocardial
infarction. Which response best reflects CMDT guidance for
primary prevention in older adults?
A. Recommend daily low-dose aspirin because age >65
automatically benefits.
B. Recommend aspirin only if her 10-year ASCVD risk is high and
bleeding risk low.
C. Advise against aspirin because it is contraindicated in all
adults >60.
D. Recommend aspirin for diabetes alone regardless of
cardiovascular risk.
, Correct Answer
B
Rationales
Correct: CMDT emphasizes individualized primary prevention
decisions — aspirin may be considered when 10-year ASCVD
risk is sufficiently high and bleeding risk is low; routine use in
older adults without individualized risk assessment is not
recommended.
A: Age alone is not an automatic indication; bleeding risk
matters.
C: Aspirin is not absolutely contraindicated in all adults >60;
blanket prohibition is incorrect.
D: Diabetes increases risk but does not automatically mandate
aspirin without weighing bleeding risk and overall ASCVD risk.
Teaching Point
Primary aspirin use requires individualized ASCVD vs bleeding-
risk assessment.
Papadakis et al. (2025). CURRENT Medical Diagnosis &
Treatment 2026 (65th Ed.). Ch. 1.
accessmedicine.mhmedical.com
3) Reference
Ch. 1 — Disease Prevention & Health Promotion
Question Stem
A 30-year-old woman is uncertain whether to receive HPV
